Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552994 | 0.91 | SYK (0.37) | SYKGRIA1ADORA2AMGLLPDE10A | |
| SCHEMBL21552844 | 0.87 | SYK (0.37) | SYKGRIA1ADORA2A | |
| SCHEMBL21564553 | 0.83 | LRRK2 (0.37) | SYKLRRK2 | |
| SCHEMBL21552964 | 0.82 | PFKFB3 (0.38) | SYK | |
| SCHEMBL21564472 | 0.82 | PTGS2 (0.37) | SYK | |
| SCHEMBL23258205 | 0.82 | SYK (0.39) | SYK | |
| SCHEMBL21564634 | 0.80 | SYK (0.35) | SYK | |
| SCHEMBL23258004 | 0.80 | DGAT1 (0.34) | SYK | |
| SCHEMBL21564493 | 0.79 | SYK (0.34) | SYK | |
| SCHEMBL21564498 | 0.79 | SYK (0.33) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250090-A1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | KDM1B, KDM1A, KDM2A | SYK 2651/4885GRIA1 2609/4885ADORA2A 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.